SCA
CORT icon

Sassicaia Capital Advisers’s Corcept Therapeutics CORT Stock Holding History

Sassicaia Capital Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,200
Closed -$251K – 42
2025
Q1 		$251K Buy
+2,200
New +$134K 0.91% 20

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sassicaia Capital Advisers's CORT Position: Q2 2025 in Review

Sassicaia Capital Advisers sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 2,200 shares — an estimated $251K sold.

Sassicaia Capital Advisers first reported a position in CORT in Q1 2025 and held it in 1 quarter. The position peaked at $251K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Sassicaia Capital Advisers reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 2,200 Corcept Therapeutics shares in Q2 2025, an estimated $251K.
  • Sassicaia Capital Advisers first reported a position in Corcept Therapeutics in Q1 2025 and held it in 1 quarter.
  • Sassicaia Capital Advisers's Corcept Therapeutics position peaked at $251K in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Sassicaia Capital Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.